← Leaderboards
Ralph D Sanderson
University Of Arkansas Med Scis Ltl Rock
$13,345,395
Attributed
$13,475,964
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$13,475,964 · 8
By mechanism
R01$11,517,187 · 6
P01$1,697,639 · 1
R21$261,138 · 1
Top collaborators
- Elizabeth E Brown2 shared
Most similar at University Of Arkansas Med Scis Ltl Rock
Same institution · by research overlap
- Paul D Drew$5,103,668
- Tammy L Kielian$23,568,259
- Cynthia J.m. Kane$5,362,659
- Jun-Ming Zhang$18,785,905
- Gur Prasad Kaushal$1,051,957
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaNeoplastic CellNeoplasm MetastasisTumorMalignant NeoplasmsProteinsGrowthIn VivoHeparanasePlayPharmaceutical PreparationsDesignSuccessCellsTumor GrowthInhibitor/AntagonistPhenotypeCancer CellSyndecanCancer TherapyEnzymesIn VitroResourcesBone Marrow
Grant awards (49)
Heparanase in Tumor Progression, Metastasis and Chemoresistance$342,011
R01 · FY2021 · CA · contact PI
Heparanase in Tumor Progression, Metastasis and Chemoresistance$342,011
R01 · FY2020 · CA · contact PI
Heparanase in Tumor Progression, Metastasis and Chemoresistance$343,602
R01 · FY2019 · CA · contact PI
Heparanase in Tumor Progression, Metastasis and Chemoresistance$354,229
R01 · FY2018 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$330,750
R01 · FY2018 · CA · contact PI
Heparanase in Tumor Progression, Metastasis and Chemoresistance$366,354
R01 · FY2017 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$330,750
R01 · FY2017 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$330,750
R01 · FY2016 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$330,750
R01 · FY2015 · CA · contact PI
The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma$136,172
R21 · FY2015 · CA
Novel Heparanase Inhibitors for Cancer Therapy$352,380
R01 · FY2014 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$330,750
R01 · FY2014 · CA · contact PI
The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma$124,966
R21 · FY2014 · CA
Novel Heparanase Inhibitors for Cancer Therapy$372,712
R01 · FY2013 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$308,263
R01 · FY2013 · CA · contact PI
Novel Heparanase Inhibitors for Cancer Therapy$403,257
R01 · FY2012 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$330,214
R01 · FY2012 · CA · contact PI
Heparanase regulation of tumor host interactions in myeloma and breast cancer$291,206
R01 · FY2012 · CA · contact PI
Novel Heparanase Inhibitors for Cancer Therapy$333,895
R01 · FY2011 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$331,046
R01 · FY2011 · CA · contact PI
Heparanase regulation of tumor host interactions in myeloma and breast cancer$291,204
R01 · FY2011 · CA · contact PI
Novel Heparanase Inhibitors for Cancer Therapy$368,525
R01 · FY2010 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$342,171
R01 · FY2010 · CA · contact PI
Heparanase regulation of tumor host interactions in myeloma and breast cancer$300,212
R01 · FY2010 · CA · contact PI
Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy$367,802
R01 · FY2009 · CA · contact PI
Heparanase regulation of tumor host interactions in myeloma and breast cancer$294,325
R01 · FY2009 · CA · contact PI
Heparanase regulation of tumor host interactions in myeloma and breast cancer$297,000
R01 · FY2008 · CA · contact PI
Targeting Heparan Sulfate for Myeloma Therapy$279,477
P01 · FY2008 · CA · contact PI
Role of heparanase in osteolytic bone metastasis$304,164
R01 · FY2007 · CA · contact PI
Targeting Heparan Sulfate for Myeloma Therapy$277,254
P01 · FY2007 · CA · contact PI
Role of heparanase in osteolytic bone metastasis$313,515
R01 · FY2006 · CA · contact PI
Targeting Heparan Sulfate for Myeloma Therapy$199,612
P01 · FY2006 · CA · contact PI
Role of heparanase in osteolytic bone metastasis$42,648
R01 · FY2006 · CA · contact PI
Role of heparanase in osteolytic bone metastasis$260,010
R01 · FY2005 · CA
Targeting Heparan Sulfate for Myeloma Therapy$193,881
P01 · FY2005 · CA
Role of heparanase in osteolytic bone metastasis$86,156
R01 · FY2005 · CA
Role of heparanase in osteolytic bone metastasis$17,725
R01 · FY2005 · CA
Role of heparanase in osteolytic bone metastasis$314,275
R01 · FY2004 · CA
SYNDECAN FUNCTION ON MYELOMA CELLS$295,650
R01 · FY2004 · CA
Targeting Heparan Sulfate for Myeloma Therapy$188,317
P01 · FY2004 · CA
Heparanase in osteolytic bone metastasis$314,275
R01 · FY2003 · CA
SYNDECAN FUNCTION ON MYELOMA CELLS$295,650
R01 · FY2003 · CA
SYNDECAN FUNCTION ON MYELOMA CELLS$295,650
R01 · FY2002 · CA
REGULATION OF MYELOMA CELL GROWTH BY SYNDECAN 1$279,549
P01 · FY2002 · CA
SYNDECAN FUNCTION ON MYELOMA CELLS$295,650
R01 · FY2001 · CA
REGULATION OF MYELOMA CELL GROWTH BY SYNDECAN 1$279,549
P01 · FY2001 · CA
SYNDECAN FUNCTION ON MYELOMA CELLS$295,650
R01 · FY2000 · CA
REGULATION OF MYELOMA CELL GROWTH BY SYNDECAN 1$0
P01 · FY2000 · CA
REGULATION OF MYELOMA CELL GROWTH BY SYNDECAN 1$0
P01 · FY2000 · CA